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We wanted to study cyclin A as a marker for prognosis and chemotherapy response. A total of 283 women with metastatic breast
cancer were initially enrolled in a randomised multicentre trial comparing docetaxel to sequential methotrexate-fluorouracil (MF) in
advanced breast cancer after anthracycline failure. Paraffin-embedded blocks of the primary tumour were available for 96 patients
(34%). The proportion of cells expressing cyclin A was determined by immunohistochemistry using a mouse monoclonal antibody to
human cyclin A. Response evaluation was performed according to WHO recommendations. The median cyclin A positivity of
tumour cells was 14.5% (range 1.2–45.0). Cyclin A correlated statistically significantly to all other tested proliferation markers (mitotic
count, histological grade and Ki-67). A high cyclin A correlated significantly to a shorter time to first relapse, risk ratio (RR) 1.94 (95%
CI 1.24–3.03) and survival from diagnosis, RR 2.49 (95% CI 1.45–4.29), cutoff point for high/low proliferation group 10.5%. Cyclin A
did not correlate to chemotherapy response or survival after anthracycline, docetaxel or MF therapy. Of all tumour biological factors
tested (mitotic count, histological grade and Ki-67), cyclin A seemed to have the strongest prognostic value. Cyclin A is a good marker
for tumour proliferation and prognosis in breast cancer. In the present study, cyclin A did not predict chemotherapy response.
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Chemotherapy has an essential role in the treatment of both local
and advanced breast cancer (Anonymous, 1998; Crown et al, 2002).
Since not all patients benefit from aggressive chemotherapy,
identifying factors predicting poor prognosis and chemotherapy
response would be of most importance. The measurements of the
proliferative cell fraction are widely used to evaluate the tumour
growth rate and to establish the prognosis in cancer patients. High
proliferation activity correlates strongly with poor prognosis in
breast cancer, irrespective of the methodology used. According to
a recent review, counting the cells in mitosis is the most
reproducible and independent of the various markers for tumour
proliferation, while Ki-67 labelling and cyclin A index are
promising alternatives (van Diest et al, 2004). Mitotic count is
the most important constituent of the histological grade (Genestie
et al, 1998).
Cyclins and cyclin-dependent kinases regulate the cell cycle at
specific points. Cyclin A is essential in the S phase for DNA
replication, it is also involved in G2–M-phase transition (Zindy
et al, 1992; Fan and Bertino, 1997), and is therefore one of the most
useful markers signifying proliferating cells. Overexpression of
cyclin A has been associated with worse prognosis for breast
cancer in several studies (Bukholm et al, 2001; Michalides et al,
2002; Michels et al, 2002), but the results have not been consistent
(Kuhling et al, 2003; Rudolph et al, 2003). Since the lack of
prognostic significance of cyclin A is mainly seen in patients with
lymph node-negative breast cancer, it is possible that cyclin A
plays a more important role in aggressive tumours and metastatic
disease (Kuhling et al, 2003).
Of various tumour biological factors, including different
proliferation markers, only the S-phase fraction seems to be
uniformly associated with response to preoperative chemotherapy,
but not in metastatic disease (Sjo ¨stro ¨m, 2002). No predictive
markers for the chemotherapy response are presently in use in the
treatment of advanced breast cancer.
High cyclin A score predicted a better chemotherapy response
and longer progression-free survival in patients with soft tissue
sarcoma (Huuhtanen et al, 1999). To our knowledge, there are no
studies of cyclin A as a predictive marker for chemotherapy
response in metastatic breast cancer. The purpose of the present
study is to evaluate cyclin A as a marker for tumour aggressiveness
and chemotherapy response in patients with advanced breast
cancer treated in a randomised trial (Sjo ¨stro ¨m et al, 1999).
PATIENTS AND METHODS
Patients
The study is based on a phase III multicentre trial, where 140
patients were randomly allocated to receive intravenous metho-
trexate and 5-fluorouracil, and 143 to receive intravenous
docetaxel until disease progression as second-line therapy for
metastatic breast cancer between December 1994 and October 1997
(Sjo ¨stro ¨m et al, 1999). The patients were required to have
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shistologically proven primary breast cancer that had progressed
during or after the first-line anthracycline-containing treatment
for metastatic disease, or that had relapsed within 12 months after
discontinuation of adjuvant anthracycline-containing regimen.
The patients had to be 18–70 years old with a performance status
p2, and have no more than one previous chemotherapy regimen
for advanced disease (multiple endocrine treatments and radio-
therapy were allowed). Patients with measurable lesions or
evaluable lesions were eligible. Response evaluation for docetaxel
and methotrexate-fluorouracil (MF) treatment was carried out
during every third course, at treatment discontinuation and every
3 months during follow-up. Anthracycline response was evaluated
retrospectively from patient documents. Response evaluation was
performed according to WHO recommendations (Miller et al,
1981). All patients with histological blocks from the primary
tumour available for analysis were included in this study. All
stainings were reviewed, classified and regraded by one of the
authors (RMA), who did not have access to clinical data.
Characteristics of the primary tumours at the time of diagnosis
are shown in Table 1. Mitotic grading into three classes (1–3) was
carried out according to the recommendations of Elston and Ellis
(1991). Ethical approval was obtained for the randomised
chemotherapy study, including subsequent studies on biological
markers.
Immunohistochemical assays
Paraffin-embedded blocks of the primary tumour were available
for 96 patients (34%). All tissues had been fixed in 4% buffered
formalin, processed and embedded in paraffin. From each block,
5-mm-thin sections were cut on coated slides and dried overnight
at 371C. Sample deparaffination was performed in xylene and
rehydration in alcohol to distilled water. Antigen demasking was
carried out by heating the samples in a microwave oven (850W) in
citric acid buffer (pH 6.0) for 20min, buffer was added in need.
Treatment with 1.6% methanolperoxidase was used to inhibit
endogenous peroxidase activity. For immunohistochemistry
(IHC), the specimens were incubated overnight at room tempera-
ture with 1:100 diluted mouse monoclonal antibody to human
cyclin A (Novocastra, Newcastle, UK) and for Ki-67 determination
with 1:500 mouse anti-human monoclonal Mib-1 antibody
(Immunotech, Marseille, France). The binding of the primary
antibody was detected by a peroxidase-conjugated secondary
antibody using an Elite ABC Kit (Vectastain, Vector Laboratories,
Burlingame, CA, USA). As positive and negative controls for cyclin
A stainings, we used hyperplastic tonsil tissue in cyclin A stainings.
The primary antibody was omitted from negative controls.
For quantification of the immunostaining, the tumour area with
the highest density of positive nuclear staining was chosen. To
calculate the percentage of positively stained nuclei, an ocular grid
of 100 (10 10) squares was used at 10 40 magnification. All
positive nuclei from this area were counted. To estimate the
negative nuclei in the same area of 100 squares, three different
rows of 10 squares were counted and the mean score multiplied by
10. In the case of tumours with scarce cellularity, several fields
were evaluated, and negative nuclei were counted from the whole
grid area of 100 squares. The percentage of positive nuclei was
estimated by dividing the number of positively stained cells by the
entire number of cells in the same area.
Statistical methods
Statistical analyses were carried out using Macintosh SPSS
statistical software package. The association of TNM stage and
tumour characteristics with cyclin A was tested with Spearman
correlation coefficient for ordinal variables and Student’s t-test for
dichotomous variables. The association between different prolif-
eration markers was tested by computing the nonparametric
Spearman correlation coefficient. The association between treat-
ment response and proliferation markers was measured by
computing the Pearson correlation coefficient with CR classified
as 4, PR as 3, NC as 2 and PD as 1, and proliferation markers as
continuous variables. Overall survival (OS) and time to first
relapse (TFR) curves were prepared by the Kaplan–Meier method,
and prognostic variables were tested using the Cox regression
analysis with proliferation markers as continuous variables. Due to
multiple comparisons, a significance level of 0.01 was chosen. The
impact of proliferation rate and grade on TTP and OS was tested
with rates as both continuous and discrete (high/low) variables.
The results were similar with these two methods. Groups with high
and low proliferation rates were divided with cutoff points
corresponding to Ki-67 of 25%, with the aid of linear regression
analysis. A linear equation of the form y¼kx was formed by
regressing cyclin A and mitotic grade, respectively, against Ki-67.
The cutoff point was obtained by inserting the value of 25 as x and
solving the equation for y. Consequently, the cutoffs for the three
different proliferation measurements were 25, 10.5% and grade 3
for Ki-67, cyclin A and mitotic grade, respectively. These cut-
points identified about 65% in the high-risk groups for all markers
(Table 1).
RESULTS
The median cyclin A positivity of tumour cells was 14.5% (range
1.2–45.0). The frequency distributions of all tested proliferation
markers (mitotic count, histological grade, Ki-67 and cyclin A) are
presented in Table 1. Tumour characteristics at the time of
diagnosis according to cyclin A positivity are presented in Table 2.
All proliferation markers correlated highly statistically signifi-
cantly to each other, Po0001. The strongest correlation was
between Ki-67 and cyclin A, Spearman correlation coefficient 0.74.
Table 1 Characteristics of the primary tumours at the time of diagnosis
and time to first relapse (TFR) of the 96 investigated patients
Factor No. of patients (%) Median (range)
Histology
Ductal 94 (98)
Lobular 2 (2)
Oestrogen receptor status
Positive 48 (50)
Negative 39 (41)
Unknown 9 (9)
Mitotic count
1 12 (13)
2 29 (30)
3 55 (57)
Tumour grade
1 1 (1)
2 32 (33)
3 63 (66)
KI-67
o25% 29 (30) 38 (10–90)
X25% 67 (70)
Cyclin A
o10.5% 33 (34) 14.5 (1.2–45)
X10.5% 63 (66)
TFR (years) 1.57 (0–22.8)
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markers are presented in Table 3.
Out of 96 patients, 58 were evaluable for response after first-line
anthracycline treatment and 96 after second-line docetaxel or MF
treatment (50 in the docetaxel group and 46 in the MF group). The
overall response rate (CRþPR) was 47% after first-line anthra-
cycline therapy, 46% in the docetaxel arm and 26% in the MF arm,
respectively. In the parent study (n¼283), the corresponding
response rates for docetaxel and MF treatment were 42 and 21%
(Sjo ¨stro ¨m et al, 1999). Association of the overall response rate
(complete or partial response) with the investigated tumour
proliferation markers is shown in Table 4. There was no significant
correlation between chemotherapy response and any proliferation
marker after anthracycline, docetaxel or MF treatment.
There was a significant association between a high cyclin A score
and TFR, risk ratio (RR) 1.03 (95% CI 1.01–1.05), P¼0.001 (as
continuous variable) and RR 1.94 (95% CI 1.24–3.03), P¼0.004
(as discrete variable), while the other markers showed only
nonsignificant trends in the same direction. There was also a
highly significant association between a high Cyclin A score and
OS from diagnosis (Figure 1), RR 1.05 (95% CI 1.02–1.07),
Po0.001 (as continuous variable) and RR 2.49 (95% CI 1.45–4.29),
P¼0.004 (as discrete variable), but not for survival from start of
first- or second-line chemotherapy. For details, see the results
presented in Table 5. Since the prognostic value of cyclin A seemed
to depend on chemotherapy, we separately analysed the associa-
tion between cyclin A and whether the patient had received
adjuvant chemotherapy or not. While the prognostic impact of
cyclin A on survival from diagnosis was significant for both
groups, the RR was somewhat higher in patients who did not
receive adjuvant chemotherapy RR 1.07 (95% CI 1.03–1.10)
compared to patients who were given adjuvant chemotherapy RR
1.03 (95% CI 1.00–1.06).
DISCUSSION
The main finding of the present study was the significant
association of a high cyclin A with a short TFR and poor survival.
The difference in survival from diagnosis of breast cancer was
quite remarkable, despite the fact that all patients developed
metastatic disease, since the patient material was recruited from a
study in metastatic disease. We used a cutoff value of 10.5% for the
high and low cyclin A positivity groups. This is in line with three
other studies, where median values varying between 8 and 11%
have been used (Michalides et al, 2002; Michels et al, 2002; Kuhling
et al, 2003; Rudolph et al, 2003). In the fourth study, four different
categories were used for cyclin A positivity and the median
category was between 15 and 30% (Bukholm et al, 2001).
We found a strong correlation between cyclin A, mitotic count,
tumour grade and Ki-67, which is in line with previous studies in
breast cancer (Michalides et al, 2002; Michels et al, 2002). Cyclin A
was the only marker that showed a statistically significant
correlation to both TFR and OS; therefore, it seems to be the
most useful marker of proliferation. There are some well-known
Table 2 Tumour characteristics at the time of diagnosis according to
cyclin A positivity
Cyclin
Ao10.5%
Cyclin
A410.5%
Tumour characteristic
No. of
patients (%)
No. of
patients (%) P-value
Tumour size
0–2cm 10 (30) 14 (22)
2.1–5cm 12 (36) 29 (46)
45cm 4 (12) 9 (14)
Direct extension to skin
or chest wall
2 (6) 4 (6) NS
Unknown 5 (15) 7 (11)
Nodal status
Negative 12 (36) 19 (30)
Positive 18 (55) 36 (57)
Fixed lymph nodes 2 (6) 7 (11)
Unknown 1 (3) 1 (2) NS
Primary metastatic disease
No 23 (70) 51 (81)
Yes 6 (18) 7 (11)
Unknown 4 (12) 5 (8) NS
Hormone receptor status
ER+ 10 (30) 29 (46)
ER  21 (64) 27 (43)
Unknown 2 (6) 7 (11) P¼0.003
Histology
Ductal 31 (94) 63 (100)
Lobular 2 (6)
c-erb-B2
Low 5 (15) 29 (46)
Intermediate 3 (9) 16 (25)
High 11 (33) 18 (28) NS
Grade
1 3 (9) 1 (2)
2 17 (52) 13 (21)
3 13 (39) 49 (78) Po0.001
Table 3 Spearman correlation coefficient and significance between the
investigated tumour biological factor
Grade KI-67 Cyclin A
Mitotic count 0.82 0.39 0.39
Grade 0.36 0.40
KI-67 0.74
P-value 0.001 for all comparisons.
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Figure 1 Kaplan–Meier plot for OS from diagnosis according to cyclin
A. Thin line, cyclin A o10.5%; thick line, cyclin A410.5%, P¼0.004.
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breast cancer. The duration of mitotic phase can vary and the
mitotic count is not linearly correlated to proliferating cells,
especially in aneuplodic tumours. Although histological grade
is a well-established prognostic factor, the reproducibility of
the method has been questioned (Boiesen et al, 2000). The
flow-cytometric determination of S phase requires tumour
volumes larger than immunohistochemical methods, and there is
also pronounced intratumoral heterogenity in S phase (van Diest
et al, 2004). Moreover, fresh frozen tissue is needed for S-phase
analysis and the costs for flow cytometry are higher than for
IHC. Cyclin A is expressed during the late S, G2 and M phases,
and it is therefore a useful marker for proliferating cells (Zindy
et al, 1992; Fan and Bertino, 1997). Cyclin A can be analysed
on paraffin-embedded tissue with the immunohistochemial
technique, which is an advantage both for practical and econo-
mical reasons.
An association between a high cyclin A expression and poor
prognosis has previously been described in three studies, all
executed after primary therapy for breast cancer (Bukholm et al,
2001; Michalides et al, 2002; Michels et al, 2002). A fourth study,
however, in node-negative patients showed no correlation between
cyclin A and prognosis (Kuhling et al, 2003; Rudolph et al, 2003).
Several studies have revealed an association between a high
proliferation index measured by other means and favourable
chemotherapy response. In the preoperative setting, most studies
have shown that a higher proliferation index is associated to a
higher response rate of anthracycline-based chemotherapy, while
the results in metastatic breast cancer are less consistent
(Sjo ¨stro ¨m, 2002). There are data also from other malignancies,
indicating that a higher proliferation rate correlates to a better
chemotherapy response (Joensuu et al, 1994; Hahka-Kemppinen
et al, 1997; Huuhtanen et al, 1999). We are aware of no clinical data
on cyclin A as a predictive factor for chemotherapy in breast
cancer. A preclinical study by Volm showed that breast cancer cell
lines with high cyclin A were significantly more sensitive to
doxorubicin than cell lines with low cyclin A activity (Volm et al,
1997).
Table 4 Association of the overall response rate (complete or partial response) to different chemotherapy with the investigated tumour biological factors
in patients with evaluable response to treatment
Variable
Response % to
anthracycline
treatment (n) P-value
a
Response % to
docetaxel
treatment (n) P-value
a
Response % to
MF treatment
(n) P-value
a
All tumours 47 (58) 46 (48) 26 (46)
Mitotic count
1 56 (5/9) 60 (3/5) 43 (3/7)
2 38 (6/16) 39 (7/18) 36 (4/11)
3 49 (16/33) 0.89 48 (13/27) 0.94 18 (5/28) 0.55
Tumour grade
1 100 (1/1)
2 29 (5/17) 47 (9/19) 46 (6/13)
3 53 (21/40) 0.32 47 (14/30) 0.78 18 (6/33) 0.16
KI-67
o25% 41(7/17) 43 (6/14) 47 (7/15)
X25% 49 (20/41) 0.27 47 (17/36) 0.97 16 (5/31) 0.18
Cyclin A
o10.5% 42 (8/19) 59 (10/17) 44 (7/10)
X10.5% 49 (19/39) 0.11 39 (13/33) 0.55 17 (5/30) 0.26
aP-value for the Pearson correlation coefficient.
Table 5 Cox regression analysis according to tumour biological factor (as discrete, high/low variable) and different chemotherapy regimen
Risk ratio (95% CI)
Grade Mitotic count KI-67 Cyclin A
TFR 1.50 (0.97–2.32) 1.29 (0.86–1.95) 1.36 (0.88–2.11) 1.94 (1.24–3.03)
OSdg 1.95 (1.16–3.27) 1.62 (0.99–2.65) 1.61 (0.95–2.70) 2.49 (1.45–4.29)
Efficacy parameters after anthracycline treatment
TTPa 0.46 (0.22–0.97) 0.82 (0.42–1.60) 0.83 (0.40–1.71) 0.63 (0.31–1.27)
OSa 1.11 (0.56–2.20) 1.01 (0.56–1.91) 1.28 (0.64–2.55) 1.34 (0.67–2.68)
Efficacy parameters after docetaxel or MF treatment
TTPdoc 1.02 (0.56–1.87) 0.83 (0.46–1.51) 0.63 (0.32–1.24) 1.32 (0.70–2.48)
OSdoc 1.46 (0.75–2.86) 0.65 (0.61–2.21) 0.85 (0.41–1.76) 1.90 (0.90–4.06)
TTPmf 1.30 (0.66–2.54) 1.08 (0.58–2.00) 1.19 (0.62–2.26) 1.20 (0.64–2.26)
OSmf 1.25 (0.56–2.83) 0.92 (0.46–2.02) 1.14 (0.53–2.46) 1.01 (0.48–2.13)
TFR: time to first relapse, TTPa: time to progression after anthracycline therapy, OSa: overall survival after anthracycline therapy, TTPdoc: time to progression after docetaxel
therapy, OSdg: overall survival from diagnosis, OSdoc: overall survival after docetaxel therapy, MF: methotrexate fluorouracil, TTPmf: time to progression after methotrexate
fluorouracil therapy, OSmf: overall survival after methotrexate fluorouracil therapy.
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effects are most pronounced for cells in S or G2 phase. The
antimetabolites methotrexate and 5-fluorouracil as antimetabolites
mainly inhibit the cell proliferation in the S phase, and docetaxel,
which is a microtubulin stabiliser, exerts its cytotoxic effect in the
G2M phase. Since cyclin A is active and detectable from the
beginning of the S phase to the beginning of mitosis, it should
theoretically label the proportion of cells that are sensitive to
chemotherapeutic drugs used in our study. Despite this, no
correlation between cyclin A activity and response rate, TTP and
OS calculated from the start of chemotherapy was found. A
previous study from a randomised trial comparing adjuvant
chemotherapy (cyclophosphamide, methotrexate and 5-fluoro-
uracil) to radiotherapy in primary breast cancer showed that the
benefit from chemotherapy was more pronounced among patients
with tumours with a high S-phase fraction (Stal et al, 1994). Thus,
the strong contrast between the adverse prognostic impact of a
high proliferation rate from diagnosis of the disease, but not after
start of aggressive chemotherapy, may indicate that chemotherapy
has improved the course of the disease, especially in highly
proliferating tumours.
We conclude that cyclin A seems to be the strongest prognostic
factor in a panel of proliferation markers including Ki-67 and
mitotic count in metastatic breast cancer. None of the proliferation
markers predicted chemotherapy response to the three regimens in
the study.
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